Subscribe via RSS

Tags: ipoRemove, pharmaceuticalsRemove

Equities
Shanghai Pharma raises $2 billion from Hong Kong listing
China's second-biggest drug distributor prices its H-share offering below the mid-point, but at a modest 2.4% discount versus its A-shares.
By Anette Jönsson | 16 May 2011
Equities
Liansu raises $250 million, while WWTT withdraws IPO
The increasingly selective approach by investors also works in favour of Sino Biopharmaceutical which is able to raise $144 million from an upsized placement earlier this week.
By Lillian Liu | 18 June 2010
Equities
Massive demand for Sinopharm bodes well for IPO pipeline
The Chinese pharmaceutical distributor prices at the top to raise $1.13 billion after attracting $110 billion worth of orders. Separately, Digital China raises $49 million from ...
By Anette Jönsson | 17 September 2009
Equities
Sinopharm sets price range for $1.13 billion IPO
The Chinese distributor of pharmaceutical products will be the first company to take orders for a Hong Kong listing after the summer and has set the price range at HK12.25 to ...
By Anette Jönsson | 4 September 2009
Equities
United Laboratories prices Hong Kong IPO at the top
Institutional investors get 70% of the $105 million offering from the Chinese drug maker. Retail subscriptions are less overwhelming.
By Anette Jönsson | 11 June 2007
Equities
Chinese drug maker seeks Hong Kong listing
IPO investors will need to weigh up United Laboratories' strong structural growth potential and generous valuation against a regulated market with plenty of competition and ...
By Anette Jönsson | 29 May 2007
Equities
Simcere breaks negative trend for Chinese listings in the US
The pharmaceutical company trades up 5.5% after pricing its $226.5 million IPO at the top of the range.
By Anette Jönsson | 23 April 2007
Equities
Tongjitang prices US IPO 33% below initial price range
The Chinese medicine maker becomes the first Mainland company to cut the size of a US offering this year as the fall-out from the equity market correction broadens.
By Anette Jönsson | 19 March 2007
Equities
Chinese drug maker seeks NYSE listing
The company banks on an ageing Chinese population and higher urban wealth to drive growth of its key drug.
By Anette Jönsson | 1 March 2007
Equities
Wuyi prices IPO at top end, Meadville in the upper half of the range
The first two Hong Kong IPOs of size this year raise $255 million between them. Retail demand remains strong, triggering full clawbacks on both deals.
By Anette Jönsson | 29 January 2007
Equities
Drug maker and PCB manufacturer launch first HK IPOs for 2007
Hong Kong companies Wuyi Pharmaceutical and Meadville seek to raise a combined $265 million with trading debuts scheduled for the first two days of February.
By Anette Jönsson | 18 January 2007
1
Tag Filters
ccb international china cicc citigroup credit suisse deutche bank drugs electronics fabrics goldman sachs h share healthcare hsbc liansu merrill lynch morgan stanley nyse pcb pipe placement sino biopharm sinopharm textiles touch pad ubs united laboratories water supply wwtt
MOST READ
Polls
With Valentine's Day approaching, who would make the best match for Olympus?
   |   View results
Nikon
  23%
 
Sony
  16%
 
Panasonic
  20%
 
Fujifilm
  22%
 
Samsung
  19%
TOTAL VOTES: 64

 
View previous polls »
LATEST FROM AsianInvestor
Latest headlines from AsianInvestor
More from AsianInvestor »
WEBCASTS
On Demand Webcasts
View all webcasts »
Tables
Latest League Tables » Dealogic
DCM | ECM | M&A | Fees
Debt Pipeline »
Equity Pipeline »
Magazine
FinanceAsia Magazine
FinanceAsia
December 2011/January 2012